Literature DB >> 9532276

Magnetic resonance spectroscopy guided brain tumor resection: differentiation between recurrent glioma and radiation change in two diagnostically difficult cases.

M C Preul1, R Leblanc, Z Caramanos, R Kasrai, S Narayanan, D L Arnold.   

Abstract

BACKGROUND: It is often difficult to differentiate a recurrent glioma from the effects of post-operative radiotherapy by means of conventional neurodiagnostic imaging. Proton magnetic resonance spectroscopic imaging (1H-MRSI), that allows in vivo measurements of the concentration of brain metabolites such as choline-containing phospholipids (Cho), may provide in vivo biochemical information helpful in distinguishing areas of tumor recurrence from areas of radiation effect. PATIENTS AND METHODS: Two patients who had undergone resection and post-operative radiotherapy for a cerebral glioma became newly symptomatic. Computed tomographic (CT) and magnetic resonance imaging (MRI) performed after the intravenous infusion of contrast material, and in one case, [18F]fluorodeoxyglucose positron emission tomography (PET), could not differentiate between the possibilities of recurrent glioma and radiation effect. The patients underwent 1H-MRSI prior to reoperation and the 1H-MRSI results were compared to histological findings originating from the same locations.
RESULTS: A high Cho signal measured by 1H-MRSI was seen in areas of histologically-proven dense tumor recurrence, while low Cho signal was present where radiation changes predominated.
CONCLUSIONS: The differentiation between the recurrence of a cerebral glioma and the effects of post-operative irradiation was achieved using 1H-MRSI in these two patients whose conventional neurodiagnostic imaging was equivocal for such a distinction. Where these two conditions are present, metabolite images from 1H-MRSI, such as that based on Cho, can be co-registered with other imaging modalities such as MRI and may also be integrated with functional MRI or functional PET within a multimodal imaging-guided surgical navigation system to assure maximal resection of recurrent tumor while minimizing the risk of added neurological damage.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9532276     DOI: 10.1017/s0317167100033436

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  14 in total

1.  Early prediction of response to Vorinostat in an orthotopic rat glioma model.

Authors:  Li Wei; Samuel Hong; Younghyoun Yoon; Scott N Hwang; Jaekeun C Park; Zhaobin Zhang; Jeffrey J Olson; Xiaoping P Hu; Hyunsuk Shim
Journal:  NMR Biomed       Date:  2012-02-02       Impact factor: 4.044

2.  Differentiation between treatment-related changes and progressive disease in patients with high grade brain tumors using support vector machine classification based on DCE MRI.

Authors:  Moran Artzi; Gilad Liberman; Guy Nadav; Deborah T Blumenthal; Felix Bokstein; Orna Aizenstein; Dafna Ben Bashat
Journal:  J Neurooncol       Date:  2016-01-11       Impact factor: 4.130

3.  MR imaging and single-photon emission CT findings after gene therapy for human glioblastoma.

Authors:  F W Floeth; A Aulich; K J Langen; K J Burger; W J Bock; F Weber
Journal:  AJNR Am J Neuroradiol       Date:  2001-09       Impact factor: 3.825

4.  Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy.

Authors:  H P Schlemmer; P Bachert; K K Herfarth; I Zuna; J Debus; G van Kaick
Journal:  AJNR Am J Neuroradiol       Date:  2001-08       Impact factor: 3.825

5.  201Thallium SPECT and 1H-MRS compared with MRI in chemotherapy monitoring of high-grade malignant astrocytomas.

Authors:  K Kallén; I M Burtscher; S Holtås; E Ryding; I Rosén
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

Review 6.  Imaging of brain tumors: MR spectroscopy and metabolic imaging.

Authors:  Alena Horská; Peter B Barker
Journal:  Neuroimaging Clin N Am       Date:  2010-08       Impact factor: 2.264

7.  Efficacy of proton magnetic resonance spectroscopy in clinical decision making for patients with suspected malignant brain tumors.

Authors:  A Lin; S Bluml; A N Mamelak
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

8.  Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma.

Authors:  J J Raizer; J A Koutcher; L E Abrey; K S Panageas; L M DeAngelis; E Lis; S Xu; K L Zakian
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

9.  Magnetic resonance spectroscopy in pediatric neuroradiology: clinical and research applications.

Authors:  Ashok Panigrahy; Marvin D Nelson; Stefan Blüml
Journal:  Pediatr Radiol       Date:  2009-11-24

10.  Metabolism of diffuse intrinsic brainstem gliomas in children.

Authors:  Ashok Panigrahy; Marvin D Nelson; Jonathan L Finlay; Richard Sposto; Mark D Krieger; Floyd H Gilles; Stefan Blüml
Journal:  Neuro Oncol       Date:  2007-11-14       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.